QT Sense Secures €4M to Advance Quantum Nanodiamond Platform for Real-Time Cellular Drug Discovery
Key Insights
QT Sense (search) raised €4 million to accelerate development of Quantum Nuova, a quantum-sensing platform that uses fluorescent nanodiamond sensors to monitor cellular processes in real-time.
The platform enables researchers to observe oxidative stress (search), metabolic shifts (search), and free radical kinetics (search) at single-cell resolution in living cells, unlike traditional methods requiring fixed tissue samples.
The technology has already characterized mechanism-of-action for several FDA-approved drugs and will focus on colorectal cancer (search) research under the ONCO-Q grant.
QT Sense (search), a deep-tech biotech startup spun out of the University Medical Center Groningen, has secured €4 million in funding to accelerate development of its Quantum Nuova platform, a breakthrough quantum-sensing technology that enables real-time observation of cellular processes in living cells. The funding round consists of a €3 million seed investment led by Cottonwood Technology Fund (search) with participation from QDNL Participations (search), supplemented by a €600,000 ONCO-Q grant for cancer (search) research and €400,000 from the Quantum Forward Challenge.
Revolutionary Approach to Cellular Analysis
The Quantum Nuova platform represents a significant departure from traditional spatial biology methods that require fixed or non-living tissue samples. The technology utilizes fluorescent nanodiamond quantum sensors to monitor oxidative stress (search), metabolic shifts (search), and free radical kinetics (search) at single-cell resolution in living cells. These ultra-sensitive nanodiamonds contain special defects that glow when exposed to laser light, with the fluorescence changing in response to chemical signals within cells.
Unlike conventional laboratory methods that provide only static snapshots of cellular biology, Quantum Nuova leverages the magnetometry and confocal microscopy properties of nanodiamonds to track biochemical activity in situ. This allows researchers to observe how individual cells respond to external stressors or pharmaceutical compounds without destroying the cellular environment.
Clinical Applications and Drug Discovery Impact
The platform has already demonstrated its utility in characterizing the mechanism-of-action for several FDA-approved drug compounds. The technology enables scientists to see how individual cells react to drugs, adapt to stress, or differentiate into subgroups, providing insights beyond what genetics, traditional imaging, or fixed-cell methods can deliver.
These capabilities are particularly valuable for understanding diseases like cancer (search), sepsis (search), and chronic inflammatory conditions (search), where oxidative stress (search) and metabolic processes play crucial roles in disease development and treatment response. The signals detected by the nanodiamond sensors are central to these pathological processes but have been difficult to observe directly until now.
Cancer Research Focus and Technical Development
Under the ONCO-Q grant, QT Sense (search) plans to apply the technology specifically to colorectal cancer (search) research, mapping oxidative stress (search) and metabolic vulnerabilities in tumor models. This work aims to support the development of future diagnostics and therapies by providing unprecedented insight into how cancer (search) cells behave in real-time.
The company's technical roadmap includes transitioning the current high-performance prototype into a deployable discovery platform for laboratories and drug discovery programs. Planned hardware improvements focus on increasing throughput, enhancing system robustness for laboratory environments, and integrating automated analytics for functional heterogeneity profiling across multiple samples.
Market Positioning and Future Deployment
QT Sense (search) was established in 2024, building on academic research into quantum sensing and cellular biology developed at the University Medical Center Groningen. The funding will enable the company to advance from prototype to commercial deployment, with early access units expected to be provided to strategic partners for validation and real-world use cases.
The platform addresses a critical gap in current research capabilities by providing a live view of cell behavior at the individual cell level. This dynamic perspective could help researchers uncover new insights about disease mechanisms, drug efficacy, and treatment optimization that are missed by conventional static analysis methods.